Daily Alert – 9/11/19
This specialty chemical company beat analysts’ revenue estimates, posting sales of $484.5 million.
Read More
This specialty chemical company beat analysts’ revenue estimates, posting sales of $484.5 million.
Read More
Although second quarter was challenging for this healthcare REIT, analysts see the future as brightening, with growth estimates of 16.70% for next year.
Read More
While this preferred stock has been volatile, the yield is attractive for speculative investors.
Read More
The shares of this healthcare REIT were recently upgraded by Wells Fargo and Raymond James to ‘Strong Buy’.
Read More
Our second idea is a sale of a previous choice.
Read More
Our first recommendation beat analysts’ EPS estimates by $0.32 last quarter
Read More
This resource company faces an improving marketplace and pays an annual dividend yield of 5.72%, paid quarterly.
Read More
This P&C insurance company is building its reach with acquisitions.
Read More
Five analysts have recently increased their EPS estimates for this specialty lending company.
Read More
This global chemical company is forecasted to grow 27.7% this year, but trades at a P/E of just 12.14.
Read More